Board of Directors

Christopher D. Earl is President of Innotrove, LLC., through which he advises leading venture funds and biopharmaceutical companies. He serves on the boards of several biotechnology companies and science-driven philanthropic organizations. He was the first President and CEO of BIO Ventures for Global Health, a non-profit organization that drives biotech investment in researching cures for infectious diseases of the developing world. Dr. Earl also served as Managing Director of Perseus Capital and the Perseus-Soros BioPharmaceutical Fund, and CEO of Avitech Diagnostics, Inc. Dr. Earl received a BA in Biology from the University of Pennsylvania, and a PhD in Cellular and Developmental Biology from Harvard University.
Roger Kitterman brings to Daktari more than 15 years of experience in health care venture investing, including as managing partner at Mi3 Venture Partners, an early stage, bioengineering-focused fund, and Lee Munder Venture Partners. He is currently a partner at the Partners Innovation Fund, and is a co- founder of Mass Medical Angels. Roger holds an MBA in Finance and Business Development from the Columbia Business School and an AB from Harvard College.
Stanley Lapidus is an experienced entrepreneur. He founded and served as CEO of three public companies, Cytyc, EXACT Sciences, and Helicos BioSciences. He currently serves as CEO of SynapDx Corp., which he founded in 2009 to develop novel diagnostics for autism. He teaches at the Biomedical Enterprise Program at MIT and is the inventor of 31 US patents.
Ed Roberts is Professor at the MIT Sloan School of Management, founder and chair of the MIT Entrepreneurship Center, and a prolific founder, investor and board member at numerous start-up companies in high technology. Ed’s portfolio of current and recent companies includes Advanced Magnetics, Inverness Medical, Meditech, Pegasystems,, and Visible Measures. He is the author of several books on technology and entrepreneurship, and holds four degrees from MIT, including a PhD in Economics.
Bill Rodriguez is a co-founder and the CEO of Daktari.
David M. Rubin, Ph.D., is an Managing Director in Merck’s Global Health Innovation group. David holds board seats at Asuragen, Daktari Diagnostics, Electrocore, Virtualscopics, and Prophecy. David joined Merck in 2007 as Director of Franchise and Portfolio Management. His primary responsibilities were to oversee the operational support of MRL disease area franchises and provide portfolio management support to MRL Oncology, including the development of franchise strategies, scenario planning, and portfolio valuation. David joined Merck from Cognia Corporation where he was CEO and President, and helped to build it into an R&D software and content products company. Previously, David was at The Wilkerson Group/IBM Global Services in a Strategic Management position supporting pharma, biotech, and diagnostics companies. David holds a Ph.D. from Temple University in Molecular Biology and a BA from SUNY Binghamton in Biology. He was a National Institutes of Health and American Cancer Society Post-Doctoral fellow at Harvard Medical School where he worked on the Ubiquitin Proteasome Pathway. He also received training in post-graduate business at Harvard University.
Aaron Sandoski currently serves as the managing director at Norwich Ventures. Previously, Aaron worked for DEKA, the engineering think tank of Dean Kamen, where he helped develop partnerships and formulate business plans for emerging technologies. Aaron began his career as a consultant at McKinsey & Company, where he advised healthcare clients ranging from leading medical device companies to a rural hospital system. Aaron earned an MBA from Harvard Business School and graduated from Dartmouth College with a double A.B. in Chemistry and Economics.